CD274 and non-small cell lung carcinoma: Following the publication of the IMpower110 study in 2020, numerous subsequent studies have investigated the cost-effectiveness of atezolizumab as a first-line treatment in patients with advanced or metastasis NSCLC who have favorable performance status and positive PD-L1 expression across various countries.